MA34815B1 - Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer - Google Patents

Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer

Info

Publication number
MA34815B1
MA34815B1 MA36091A MA36091A MA34815B1 MA 34815 B1 MA34815 B1 MA 34815B1 MA 36091 A MA36091 A MA 36091A MA 36091 A MA36091 A MA 36091A MA 34815 B1 MA34815 B1 MA 34815B1
Authority
MA
Morocco
Prior art keywords
inhibitor
cancer
compositions
treatment
pi3k
Prior art date
Application number
MA36091A
Other languages
English (en)
Inventor
Laurent Debussche
Carlos Garcia-Escheverria
Jianguo Ma
Stuart Mcmillan
Janet Anne Meurer Ogden
Loic Vincent
Original Assignee
Sanofi Sa
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34815(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Merck Patent Gmbh filed Critical Sanofi Sa
Publication of MA34815B1 publication Critical patent/MA34815B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés de traitement de patients avec cancer, dans lesquels les procédés comprennent l'administration au patient d'une quantité efficace d'un inhibiteur de MEK et d'une quantité efficace d'un inhibiteur de PI3K. Les compositions dans lesquelles les inhibiteurs de MEK et de PI3K sont combinés sont aussi décrites.
MA36091A 2010-12-09 2011-12-08 Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer MA34815B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42146510P 2010-12-09 2010-12-09
US201161436258P 2011-01-26 2011-01-26
US201161467485P 2011-03-25 2011-03-25
FR1159940 2011-11-03
PCT/US2011/063871 WO2012078832A1 (fr) 2010-12-09 2011-12-08 Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA34815B1 true MA34815B1 (fr) 2014-01-02

Family

ID=45464841

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36091A MA34815B1 (fr) 2010-12-09 2011-12-08 Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer

Country Status (23)

Country Link
US (1) US20140024653A1 (fr)
EP (1) EP2648729A1 (fr)
JP (1) JP2013544892A (fr)
KR (1) KR20140011311A (fr)
CN (1) CN103402518A (fr)
AR (1) AR084216A1 (fr)
AU (1) AU2011338354A1 (fr)
BR (1) BR112013014198A2 (fr)
CA (1) CA2820748A1 (fr)
CL (1) CL2013001643A1 (fr)
CR (1) CR20130246A (fr)
DO (1) DOP2013000131A (fr)
MA (1) MA34815B1 (fr)
MX (1) MX2013006319A (fr)
NZ (1) NZ611581A (fr)
PE (1) PE20140702A1 (fr)
PH (1) PH12013501163A1 (fr)
RU (1) RU2013131241A (fr)
SG (1) SG190368A1 (fr)
TW (1) TW201306837A (fr)
UY (1) UY33790A (fr)
WO (1) WO2012078832A1 (fr)
ZA (1) ZA201303687B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854854A1 (fr) * 2012-04-06 2015-04-08 Sanofi Méthodes de traitement du cancer à l'aide d'un inhibiteur de pi3k et d'un inhibiteur de mek
WO2014056566A1 (fr) * 2012-10-11 2014-04-17 Merck Patent Gmbh Association d'un dérivé de 6-oxo-1,6-dihydro-pyridazine présentant une activité anticancéreuse à un inhibiteur de mek
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
WO2016014390A1 (fr) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions et méthodes pour polythérapie à base d'inhibiteurs de mek dans le traitement du cancer
PL3729085T3 (pl) * 2017-12-22 2026-02-16 Adienne S.A. Ilościowy sposób komórkowy do określania aktywności biologicznej ligandu anty-cd26
WO2021047783A1 (fr) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 en combinaison avec ch5126766 pour le traitement du cancer
EP4228759A1 (fr) * 2020-10-16 2023-08-23 Memorial Sloan Kettering Cancer Center Induction de la ferroptose pour la thérapie du cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
US20140024653A1 (en) 2014-01-23
KR20140011311A (ko) 2014-01-28
TW201306837A (zh) 2013-02-16
JP2013544892A (ja) 2013-12-19
NZ611581A (en) 2015-02-27
CR20130246A (es) 2013-09-03
ZA201303687B (en) 2014-01-29
DOP2013000131A (es) 2013-11-15
WO2012078832A1 (fr) 2012-06-14
BR112013014198A2 (pt) 2016-09-13
CA2820748A1 (fr) 2012-06-14
CL2013001643A1 (es) 2014-03-28
RU2013131241A (ru) 2015-01-20
MX2013006319A (es) 2013-07-03
CN103402518A (zh) 2013-11-20
SG190368A1 (en) 2013-06-28
EP2648729A1 (fr) 2013-10-16
PE20140702A1 (es) 2014-06-26
AR084216A1 (es) 2013-05-02
UY33790A (es) 2012-07-31
AU2011338354A1 (en) 2013-06-27
PH12013501163A1 (en) 2013-07-29

Similar Documents

Publication Publication Date Title
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
IN2015DN00376A (fr)
MA37829A1 (fr) Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
PH12014501560A1 (en) Carbamate compounds and of making and using same
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
MX2019007351A (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
EA201370230A1 (ru) Новые ингибиторы rock
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201490254A1 (ru) Комбинированное лечение гепатита с
UA112434C2 (uk) Антигензв'язувальний білок, який специфічно зв'язується з всма
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
EA200971053A1 (ru) Способы лечения кожных язв
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
MX2014005749A (es) Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp).
WO2008073466A3 (fr) Alpha b-cristalline en tant que traitement de l'inflammation
MX357770B (es) Ácidos nucleicos de enlace sdf-1 y el uso de los mismos en el tratamiento de cáncer.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
MA37930A1 (fr) Procédés pour le traitement du cancer utilisant le lipoplatine
EA201070844A1 (ru) ((e)-n-{3-[1-(8-фтор-11h-10-окса-1-аза-дибензо[a,d]циклогептен-5-илиден)пропил]фенил}метансульфонамид) в качестве модулятора рецепторов глюкокортикоидов для лечения ревматизма